{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:58Z","timestamp":1793338438103,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDA0580000"],"award-info":[{"award-number":["XDA0580000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["YG2025ZD12"],"award-info":[{"award-number":["YG2025ZD12"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502419"],"award-info":[{"award-number":["82502419"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371997"],"award-info":[{"award-number":["82371997"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["25TS1405600"],"award-info":[{"award-number":["25TS1405600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["23ZR1434800"],"award-info":[{"award-number":["23ZR1434800"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015491","name":"Shanghai Institute of Technical Physics, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["SINAP-QYJS-202401"],"award-info":[{"award-number":["SINAP-QYJS-202401"]}],"id":[{"id":"10.13039\/501100015491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0909000"],"award-info":[{"award-number":["2020YFA0909000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115298","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:05:07Z","timestamp":1787587507000},"page":"115298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["A 68Ga\/161Tb-labeled FAP-targeted radioligand for enhanced theranostics: Prolonged tumor retention and metastasis inhibition"],"prefix":"10.1016","volume":"399","author":[{"given":"He","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangxi","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115298_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.115298_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225744","article-title":"Radioligands targeting fibroblast activation protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115298_bb0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint of targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115298_bb0020","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: a review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/exp2.70144","article-title":"Ultrasmall Au10\u201312 nanoclusters: a novel platform for 223Ra-targeted tumor \u03b1-therapy","volume":"6","author":"Jiang","year":"2026","journal-title":"Exploration"},{"key":"10.1016\/j.jconrel.2026.115298_bb0030","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0035","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115298_bb0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","article-title":"Fibroblast activation protein inhibitor-based radionuclide therapies: current status and future directions","volume":"64","author":"Ora","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115298_bb0045","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.2967\/jnumed.123.266983","article-title":"Fibroblast activation protein inhibitor tracers and their preclinical, translational, and clinical status in China","volume":"65","author":"Zhao","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115298_bb0050","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115298_bb0055","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00259-023-06338-6","article-title":"Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?","volume":"50","author":"Chakravarty","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0060","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1021\/acs.jmedchem.4c00448","article-title":"FAP radioligand linker optimization improves tumor dose and tumor-to-healthy organ ratios in 4T1 syngeneic model","volume":"67","author":"Lindeman","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115298_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115298_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1021\/acs.molpharmaceut.6b00738","article-title":"Optimization of curcumin-loaded PEG-PLGA nanoparticles by GSH functionalization: investigation of the internalization pathway in neuronal cells","volume":"14","author":"Paka","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115298_bb0075","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1007\/s00259-025-07362-4","article-title":"Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers","volume":"52","author":"Ye","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0080","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2967\/jnumed.124.268689","article-title":"Preclinical evaluation of 68Ga\/177Lu-labeled FAP-targeted peptide for tumor radiopharmaceutical imaging and therapy","volume":"66","author":"Wang","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115298_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejpb.2023.09.017","article-title":"Site-specific PEGylation of recombinant tissue-type plasminogen activator","volume":"192","author":"Meiners","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115298_bb0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acs.bioconjchem.8b00919","article-title":"Bench to bedside: albumin binders for improved cancer radioligand therapies","volume":"30","author":"Lau","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115298_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113757","article-title":"Development of radioligands with an albumin-binding moiety of 4-(p-iodophenyl)butyric acid for theranostic applications","volume":"382","author":"Meng","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115298_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115993","article-title":"Synthesis and preclinical evaluation of novel 18F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts","volume":"264","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115298_bb0105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115298_bb0110","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1021\/acs.chemrev.8b00281","article-title":"Radioactive transition metals for imaging and therapy","volume":"119","author":"Boros","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.115298_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115298_bb0120","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0125","doi-asserted-by":"crossref","first-page":"91S","DOI":"10.2967\/jnumed.116.186825","article-title":"Therapeutic radiometals beyond 177Lu and 90Y: production and application of promising \u03b1-particle, \u03b2\u2212-particle, and Auger electron emitters","volume":"58","author":"M\u00fcller","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115298_bb0130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00259-013-2563-z","article-title":"Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate","volume":"41","author":"M\u00fcller","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28073155","article-title":"Preclinical evaluation of [155\/161Tb]Tb-crown-TATE\u2014a novel SPECT imaging theranostic agent targeting neuroendocrine tumours","volume":"28","author":"Wharton","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115298_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","article-title":"Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection","volume":"10","author":"Verburg","year":"2023","journal-title":"EJNMMI Phys."},{"key":"10.1016\/j.jconrel.2026.115298_bb0145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists\u2014a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0150","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00259-014-2798-3","article-title":"Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model","volume":"41","author":"Gr\u00fcnberg","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115298_bb0155","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.124.268805","article-title":"161Tb radioimmunotherapy as a treatment for CD30-positive lymphomas","volume":"66","author":"Rioja-Blanco","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115298_bb0160","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1021\/acsnano.0c00974","article-title":"Enzyme-triggered transcytosis of dendrimer\u2013drug conjugate for deep penetration into pancreatic tumors","volume":"14","author":"Wang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115298_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2022.122041","article-title":"Glutathione-ascorbic acid-functionalized molybdenum oxide quantum dots-based fluorescent sensor for the detection of isoniazid drug in pharmaceutical samples","volume":"287","author":"Vajubhai","year":"2023","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jconrel.2026.115298_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.seppur.2022.120673","article-title":"Glutathione-functionalized highly crystalline fluorescent covalent organic framework as a fluorescence-sensing and adsorption double platform for cationic dyes","volume":"288","author":"Liu","year":"2022","journal-title":"Sep. Purif. Technol."},{"key":"10.1016\/j.jconrel.2026.115298_bb0175","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1021\/acs.molpharmaceut.2c01000","article-title":"Preclinical evaluation of a fibroblast activation protein and a prostate-specific membrane antigen dual-targeted probe for noninvasive prostate cancer imaging","volume":"20","author":"Wang","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115298_bb0180","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients","volume":"61","author":"Meyer","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115298_bb0185","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1021\/acs.jmedchem.4c00031","article-title":"Synthesis and preclinical evaluation of novel 99mTc-labeled FAPI-46 derivatives with significant tumor uptake and improved tumor-to-nontarget ratios","volume":"67","author":"Ruan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115298_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/ph17020256","article-title":"Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands","volume":"17","author":"de Roode","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2026.115298_bb0195","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1021\/acs.molpharmaceut.5c00464","article-title":"Structural optimization of fibroblast activation protein inhibitors through zwitterionic and PEG modification strategy: impact on pharmacokinetics and tumor imaging","volume":"22","author":"Yuan","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115298_bb0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.colsurfb.2014.11.023","article-title":"Binding of glutathione and melatonin to human serum albumin: a comparative study","volume":"125","author":"Li","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.115298_bb0205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40658-024-00696-2","article-title":"Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases","volume":"11","author":"De Nardo","year":"2024","journal-title":"EJNMMI Phys."},{"key":"10.1016\/j.jconrel.2026.115298_bb0210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1667\/RR1359.1","article-title":"Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons","volume":"170","author":"Pouget","year":"2008","journal-title":"Radiat. Res."},{"key":"10.1016\/j.jconrel.2026.115298_bb0215","doi-asserted-by":"crossref","first-page":"14019","DOI":"10.1021\/acs.jmedchem.5c01163","article-title":"Development of cysteic acid-modified FAP radioligands for enhanced renal clearance: from preclinical optimization to first-in-human study","volume":"68","author":"Peng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115298_bb0220","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/acs.molpharmaceut.3c01008","article-title":"Preclinical evaluation and a pilot clinical positron emission tomography imaging study of [68Ga]Ga-FAPI-FUSCC-II","volume":"21","author":"Du","year":"2024","journal-title":"Mol. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:28:14Z","timestamp":1793338094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"alternative-id":["S0168365926007029"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115298","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 68Ga\/161Tb-labeled FAP-targeted radioligand for enhanced theranostics: Prolonged tumor retention and metastasis inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115298"}}